Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial

LEROS Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

Leber hereditary optic neuropathy (LHON) is a mitochondrial disease leading to rapid and severe bilateral vision loss. Idebenone has been shown to be effective in stabilizing and restoring vision in patients treated within 1 year of onset of vision loss. The open-label, international, multicenter, natural history-controlled LEROS study (ClinicalTrials.gov NCT02774005) assesses the efficacy and safety of idebenone treatment (900 mg/day) in patients with LHON up to 5 years after symptom onset (N = 199) and over a treatment period of 24 months, compared to an external natural history control cohort (N = 372), matched by time since symptom onset. LEROS meets its primary endpoint and confirms the long-term efficacy of idebenone in the subacute/dynamic and chronic phases; the treatment effect varies depending on disease phase and the causative mtDNA mutation. The findings of the LEROS study will help guide the clinical management of patients with LHON.

Original languageEnglish
Article number101437
JournalCell Reports Medicine
Volume5
Issue number3
DOIs
StatePublished - 19 Mar 2024
Externally publishedYes

Keywords

  • LHON
  • Leber hereditary optic neuropathy
  • idebenone
  • mitochondrial disease
  • mtDNA
  • neuro-ophthalmology
  • optic atrophy
  • optic neuropathy
  • retinal ganglion cells

Fingerprint

Dive into the research topics of 'Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial'. Together they form a unique fingerprint.

Cite this